Compare Main Street Capital Corporation (MAIN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Smith & Nephew plc — how do they compare? Main Street Capital Corporation trades at $54.9 (market cap $5.08B), while Smith & Nephew plc trades at $30.14 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 2.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.02%). Which is the better fit depends on your goals.
| MAIN | SNN | |
|---|---|---|
Market Cap | $5.08B | $12.64B |
Sector | Financials | Health |
52-Week High | $67.54 | $38.70 |
52-Week Low | $49.63 | $28.73 |
Dividend Yield | 8.02% | 2.57% |
Enterprise Value | — | $15.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.59, down 1.41% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.93, missing expectations of $1.01, while Q4 2025 beat estimates. Revenue for 2025 was $591.85M with a net income margin of 83.36%, though 2026 projections show a decline to $526M. Analysts maintain a consensus price target of $57.75 with a 'Hold' rating predominance. Recent news highlights MAIN's dividend sustainability amid softening earnings.
MAIN offers a stable dividend yield but faces earnings pressure and revenue decline projections for 2026. The stock's valuation appears reasonable with a P/E of 11.66, yet investor caution is warranted due to mixed earnings performance and potential headwinds from Fed rate cuts impacting BDC earnings. Upside exists if the company meets or exceeds future EPS expectations, supported by its internal management cost advantage.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
